Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- Former Health Minister Masuzoe Raises Drug Re-Pricing Issues Over TPP
November 14, 2011
- 2007’s “Emergency Proposal” for Distribution Reform Needs Review: Health Ministry Councilor Mr Takeda
November 11, 2011
- Discontinuation of Vaccination Following Death due to Unknown Cause Cannot Be Considered: David Salisbury, UK Director for Vaccines and Immunization
November 11, 2011
- MHLW Calls for Package Insert Revision for Bisphosphonates
November 11, 2011
- PMDA Draws Up "Global Vision" to Establish World Class Position
November 10, 2011
- MHLW Proposes Raising GE Dispensing Rates to Receive Upper Premiums for GE Dispensing Systems
November 10, 2011
- Mr Kobayashi of Kyokai Kenpo Proposes Measures to Promote GE Drug Use
November 10, 2011
- Applications for “Regulatory Strategy Consultation” Increasing Rapidly: Mr Isobe of PMDA
November 10, 2011
- Promote “Category-based” Negotiations Instead of Package Deals: Mr Hasegawa
November 10, 2011
- PAFSC Committee Approves Extension of Reexamination Period for DSP’s Lonasen
November 9, 2011
- MHLW Announces Add’l Indications Eligible for Applications Based on Info in Public Domain
November 9, 2011
- 1st PAFSC Committee Recommends Approval for Products Including Eisai’s Lunesta
November 8, 2011
- MHLW Announces Additional Indications for 3 APIs Following Prior Assessments
November 7, 2011
- CSIMC Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 4, 2011
- CSIMC Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 4, 2011
- Japan, China, S. Korea Agree to Draft GL on Joint Clinical Trials
November 2, 2011
- Chuikyo Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 2, 2011
- Chuikyo Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 2, 2011
- Committee Recommends Approval of 3 Products Including MSD’s Rota Teq
November 1, 2011
- Business Sector Call for Japan to Join TPP Talks Voiced at National Strategy Council Meeting
November 1, 2011
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…